HER-2 status of circulating tumor cells in a metastatic breast cancer cohort: A comparative study on characterization techniques.

Background: Personalized targeted treatment in metastatic breast cancer relies on accurate assessment of molecular aberrations, e.g. overexpression of Human Epidermal growth factor Receptor 2 (HER-2).